Course Finder

Medical Biotechnology and Drug Development

Medical Biotechnology and Drug Development


Medical Biotechnology and Drug Development

About this course

This course gives you an overview of the drug discovery and development processes where disease-targeted research leads to clinical treatments. Recent advances within medical biotechnologies and the latest treatment approaches are introduced, including stem cell technology, immunotherapies, and modern vaccine development, such as those created to combat SARS-CoV-2, the virus causing COVID-19.

You will visit European pharmaceutical and biotechnology communities, university/hospital labs and start-up companies and get an insight into the business aspects of drug development and the many job niches of the field.

Syllabus

Spring 2025 – Section A

Go to syllabus

This is the most recent syllabus for this course

Spring 2025 – Section B

Go to syllabus

This is the most recent syllabus for this course

Spring 2025 – Section C

Go to syllabus

This is the most recent syllabus for this course

Pre-requisites

One year each of biology and chemistry at university level.

Faculty

dis-faculty-staff-jeanette-wern

Jeanette Erbo Wern

Faculty; Senior Research Manager

Postdoc (Inst. of International Health, Immunology and Microbiology, University of Copenhagen, Denmark, 2006-2009). Ph.D. (Immunology, Inst. Of International Health, Immunology and Microbiology, University of Copenhagen, 2005).  M.Sc. (Inst. Of International Health, Immunology and Microbiology, University of Copenhagen, 2001). Senior Scientist, Immune Targeting Group, Bioneer, Copenhagen, Denmark, 2010-2013.  Senior Scientist, Dept. of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark, 2013-2016. With DIS since 2016.

Reza Yarani

Faculty

Ph.D (Cellular and Genetic Medicine, Department of Cellular and Molecular Biology, University of Copenhagen, 2016). Assistant Professor, Translational Type 1 Diabetes Research, Department of Clinical Research, Steno Diabetes Center Copenhagen, 2021-Present. With DIS since 2023.

Kim Jacobsen

Faculty

MSc (Pharmacy, Copenhagen, 1985), Ph.D. (Biotechnology, Denmark Technical University, 1987), MBA (Sophia University, Tokyo, 1992). International Marketing, Novo Nordisk, 1994-2008. Project VP, Novo Nordisk, 2008-2014. Head of Commercial Haemophilia, Sobi Stockholm, 2014-2017. Head of Commercial Operations, Sobi Brussels/Paris, 2018-2022. Head of Commercial, Zealand Pharma, Copenhagen, 2022-2023. With DIS since 2024.